Olema Oncology Inc. (OLMA)
OLMA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | OLMA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001750284 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term." | 10-Q 2026-11-10 |
| Cash and burn | $47.5M cash; operating cash flow -$44.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 87,606,263 (2026-11-05); 68,659,923 a year earlier; 54,769,800 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-11-19 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Iselin, New Jersey, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $24.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$73.6M | -$47.1M | $47.5M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$63.2M | -$45.9M | $48.6M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | Not filed | -$53.1M | -$46.0M | $52.5M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | Not filed | -$46.1M | -$38.3M | $48.3M | No debt tags | Needs four quarters | 10-K 2026-03-16 |
| Q3 2025 2025-09-30 | Not filed | -$42.2M | -$34.5M | $35.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$43.8M | -$29.9M | $52.5M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | Not filed | -$30.4M | -$44.0M | $50.6M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | Not filed | -$33.6M | -$26.3M | $139.5M | No debt tags | Needs four quarters | 10-K 2026-03-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-12-11 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 566 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.1% |
| 1 month | +7.7% |
| 3 months | -28.1% |
| Year to date | -69.8% |
| 1 year | -4.8% |
| From 52-week high | -78.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ANL | Adlai Nortye Group Ltd. | $10.03 | -5.47% | $645.9M |
| BCAX | Bicara Therapeutics Inc. | $9.75 | -2.69% | $647.3M |
| KURA | Kura Oncology Inc. | $7.09 | -8.75% | $651.4M |
| DSGN | Design Therapeutics Inc. | $9.92 | -5.25% | $635.2M |
| NVCT | Nuvectis Pharma Inc. | $19.11 | -5.58% | $657.2M |
| IMMX | Immix Biopharma Inc. | $7.48 | -4.59% | $626.9M |
| ALMS | Alumis Inc. | $5.14 | -8.21% | $667.3M |
| JANX | Janux Therapeutics Inc. | $10.92 | -3.96% | $668.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier